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Background: Lesions deferred revascularization following fractional ﬂow reserve
(FFR) assessment have a low risk of adverse cardiac events. The variability in
risk for deferred lesion intervention (DLI) has not been evaluated previously. The
aim was to develop a prediction model to estimate the one-year risk of DLI
in coronary lesions where revascularization was not performed following FFR
assessment.
Methods: A prediction model for DLI was developed from a cohort of 721 patients
with 882 coronary lesions where revascularization was deferred based on
FFR between 10/2002 and 7/2010. DLI was deﬁned as any revascularization of
a lesion previously deferred following FFR. The ﬁnal model for DLI was developed
using stepwise Cox regression, and internally validated and calibrated using
bootstrapping techniques. An algorithm was constructed to predict the one-year risk
of DLI.
Results: During a mean (SD) follow-up period of 4.0  2.3 years, 18% of
lesions deferred after FFR underwent DLI; the one-year incidence of DLI was 5%.
Besides FFR values, the ﬁnal Cox model included several predictors of DLI (current
or former smoking, history of coronary artery disease [CAD] or prior PCI,
and multivessel CAD), and two variables negatively associated with DLI (age
and creatinine). The c statistic for the DLI prediction model was 0.66 (95% CI
0.61-0.70).
Conclusions: Patients deferred revascularization based on FFR have variation in
their risk for DLI. A clinical prediction model consisting of 5 clinical variables and
the FFR value can help predict the risk of DLI in the ﬁrst year following FFR
assessment.
TCT-84
Fractional Flow Reserve versus Angiography in Guiding Management
to Optimize Outcomes in Non-ST Elevation Myocardial Infarction
(FAMOUS – NSTEMI) Clinical Trial: Study Design and Baseline
Characteristics of Randomized Participants.
Jamie Layland1, Arvind Sood2, Nick Curzen3, Kanarath Balachandran4, Rajiv Das5,
Shahid Junejo6, Matthew M. Lee7, Nadeem Ahmed7, Ahmed M. Mahrous8,
Andrew Beck7, Hany Eteiba7, Mark C. Petrie9, Martin M. Lindsay9, Stuart Hood7,
Stuart Watkins7, Margaret B. McEntegart10, Colum Owens9, Andrew Davie7,
Eileen Peat7, Robert A. Henderson11, Andrew Briggs12, Ian Ford12,
Keith G. Oldroyd12, Colin Berry13
1Golden Jubilee National Hospital, Clydebank, United Kingdom, 2Hairmyres
Hospital, East Kilbride, United Kingdom, 3University Hospitals Southampton,
Southampton, United Kingdom, 4Royal Blackburn Hospital, Blackburn, United
Kingdom, 5Freeman Hospital, Newcastle, United Kingdom, 6City Hospitals
Sunderland, Sunderland, United Kingdom, 7Golden Jubilee National Hospital /
University of Glasgow, Glasgow, United Kingdom, 8Golden Jubilee hospital,
Glasgow, United Kingdom, 9Golden Jubilee National Hospital, Glasgow, United
Kingdom, 10Golden Jubilee National Hospital/University of Glasgow, Glasgow,
United Kingdom, 11Nottingham University Hospitals, Nottingham, United Kingdom,
12University of Glasgow, Glasgow, United Kingdom, 13University of Glasgow /
Golden Jubilee National Hospial, Glasgow, United Kingdom
Background: Invasive management guided by coronary angiography is the stan-
dard of care in NSTEMI. We hypothesized that functional assessment of coronary
stenosis severity with fractional ﬂow reserve (FFR) would have additive diagnostic,
clinical and health economic utility, as compared to angiography-guided standard
care.
Methods: A prospective multicenter randomized double-blind controlled trial in acute
NSTEMI patients with 1 coronary stenosis 30% severity (threshold for FFR
measurement) in culprit and non-culprit lesions. Patients were randomized immedi-
ately after coronary angiography to the FFR-guided group or angiography-guided
group. The study design is shown in Figure 1. The primary outcome is the between-
group difference in the proportion of patients allocated to medical management
compared to revascularization. Secondary outcomes include health outcomes, quality
of life, and healthcare costs. The minimum/average follow-up periods are 6 & 18
months, respectively.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrResults: 350 patients were randomized between Oct 2011-May 2013 in 6 UK
hospitals. The participant characteristics are: mean  SD age 6015 years, 74% men,
14% treated diabetes, 8% prior PCI and 10% prior MI. The median (IQR) time from
the index event to the initial angiogram was 3.0(2.0,6.0) days. The median (range)
GRACE Score was 180 (8,269). On average each patient had 1.90.8 angio-
graphically diseased coronary arteries (left main 10%, RCA 58%, LAD/Diagonal
54%, Cx/OM 64%).
Conclusions: The FAMOUS NSTEMI population has high risk characteristics and
differs in several ways from the FAME trial participants.Percutaneous Treatment of Mitral Valve Disease
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Background: Reverse remodeling of the left ventricle (LV) and left atrium (LA) is
a desirable outcome after mitral valve repair (MVR) for signiﬁcant mitral regurgitation
(MR). Using data from the EVEREST II randomized trial, we compared the extent of
left-sided chamber reverse remodeling between the percutaneous and surgical mitral
repair cohorts.
Methods: The EVEREST II trial is a prospective, multicenter, randomized, non-
blinded evaluation of the percutaneous MitraClip system compared in 2:1 fashion to
surgical MVR in the setting of moderate to severe MR. Four year follow up echo-
cardiographic data was available for 85 individuals with percutaneous repair (PR) and
42 with surgical repair (SR). Successful repair was deﬁned as 2+ residual MR.
Results: Baseline characteristics and LV and LA dimensions were similar in PR and
SR groups except for a greater proportion of history of heart failure in the PR group.
At 4 years, 73% (62/85) of the PR group and 93% (39/42) of the SR group had  2+
MR. LV systolic and diastolic dimensions were signiﬁcantly reduced in both groups at
4 years, although the SR group had signiﬁcantly more reverse remodeling (Table 1,acts/ORAL/Percutaneous Treatment of Mitral Valve Disease B27
